Unlocking new clinical trial insights through analytics in eCOA

Kelly:
Analytics in eCOA clinical trials are the continuous evaluation of incoming data during a trial. It is a risk-monitoring solution that uses advanced algorithms, interactive dashboards, and scientific expertise, to support real-time monitoring of eCOA data. It helps sponsors detect emerging issues early that could affect data quality, endpoint integrity, or study execution.

Especially in today’s risk-based quality management environment (for example, as reinforced by ICH E6(R3)), data analytics helps support customers’ adherence to regulatory guidelines.

Sponsors need to identify and address risks while a trial is ongoing, not after the fact. This real-time monitoring across sites, raters, and studies helps identify trends, unusual variability or outlier data, site or rater issues, and even technical problems. With that visibility, teams can take proactive action, such as retraining sites, or investigating anomalies, before those issues affect study quality or outcomes.

Kelly: 
eCOA provides more than endpoint data, it also shows how the data is being collected. Sponsors can evaluate completion timing, adherence, submission behavior, and patterns across sites, countries, devices, or rater groups.

It also provides valuable audit trail information, helping teams understand when data was entered or changed and identify patterns that may signal risk to data integrity or protocol compliance.

That visibility is critical because even a relatively small amount of wrong or questionable data in key study variables can undermine confidence in the results and create serious regulatory risk. eCOA analytics helps sponsors detect, investigate, and address issues early, before they become larger problems for the endpoint or submission.

Kelly:
The level of analytics should match the complexity, size and risk profile of the study. If there are multiple or complex eCOAs in a study, or if eCOA data is supporting primary or key secondary endpoints, these are cues that a data analytics approach should be considered. Some therapy areas lend themselves more to benefiting from data analytics, such as Neuroscience, Immunology, Dermatology, and Rheumatology, given the complex and subjective assessments, but there could be cases across the board for data analytics providing benefit to study data integrity.

For example, clinician-reported assessments in dermatology often have overlapping concepts. Inconsistent ratings across assessments can be flagged to initiate site follow-up or remediation proactively, preventing persistent rater issues.

Stacey:
This becomes more important when endpoints are subjective or the therapeutic area, protocol, or endpoints are more complex.

This comes up in many types of trials, but especially in neuroscience where many assessments rely on rater judgment, patient condition, and site experience. These factors can impact the quality of data collected and introduce variability that is not always obvious in standard reporting. In those situations, monitoring whether data is collected is not enough. Teams must also evaluate whether the data is credible and whether the endpoint is being protected.

eCOA analytics functions as an early detection system ensuring concerns are identified early enough to action when appropriate.

Stacey:
It involves continuously monitoring selected metrics throughout the study and identifying statistically unusual patterns in near real time. We often use an algorithmic-based approach alongside a holistic review of the data to identify patterns or trends. We can also link analytics to other oversight and surveillance programs such as Independent Review, to ensure a comprehensive review of all available data and quality metrics.

But identifying the signal is just the start, the real value comes from having clinical experts review the data to decide what actually matters. Something may appear unusual from a statistical perspective without posing real risk, while meaningful issues may appear subtle at first.

By combining advanced analytics with expert insight, sponsors can take the right actions, like retraining raters or increasing site support, to protect data quality and study outcomes. That partnership is what makes analytics so powerful in neuroscience trials.

Kelly:
They give teams the ability to respond earlier and with greater confidence.

When analytics is delivered through intuitive dashboards, visualizations, and drill down reporting, sponsors and CROs can quickly see where potential risks are emerging at the subject, site, or study level. That visibility makes it easier to investigate issues and prioritize action.

Stacey:
Early visibility into issues affecting sensitive endpoints, especially when clinical experts are involved, helps sponsors quickly identify what truly matters, so they can proactively address variability, support sites, and protect data quality well before the study reaches its later stages.